CENTRAL FAX CENTER

Ø 001/007

To:

Fax No. (571) 273-0876

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450

MAR 2 6 2007

| TRANSMITTAL FORM  (to be used for all correspondence after initial filing)  |   |                        | Application Number  | 10/694,978           |  |                    |
|---|---|------------------------|---|----------------------|--|--------------------|
|   |   |                        | Filing Date   | 10/27/2003           |  |                    |
|   |   |                        | First Named Inventor  | Jacqueline C. Timans |  |                    |
|   |   |                        | Art Unit  | 1646                 |  |                    |
| (to be used to all correspondence after findar fining)  |   | Examiner Name          | P.M. Mertz  |                      |  |                    |
| Total Number of Pages in This Submission 7  |   | Attorney Docket Number | DX0904KB1   |                      |  |                    |
| ENCLOSURES (Check all that apply)   |   |                        |   |                      |  |                    |
| Fe _X Amendme Af Af Extension Express A Informatio Certified C Document Response Incomplet Re   | e to Missing Parts/<br>e Application<br>esponse to Missing Parts<br>der 37 CFR 1.52.or 1.53 | Remark                 | Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application  Power of Attorney, Revocation Change of Correspondence Addres  Terminal Disclaimer  Request for Refund  CD, Number of CD(s) | 5                    | After Allow to Group  Appeal Co of Appeal Co (Appeal Now Proprietar Status Let Identify be | closure(s) (please |
| Gregory R. Bellomy, Reg. No. 48,451 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104  Signature   |   |                        |   |                      |  |                    |
| Congres 12 elle   |   |                        |   |                      |  |                    |
| Date 26-Marel - 2007  |   |                        |   |                      |  |                    |
| CERTIFICATE OF TRANSMISSION/MAILING   |   |                        |   |                      |  |                    |
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO, Fax Number (571) 273-0876, or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date Indicated below: |   |                        |   |                      |  |                    |
| Typed or printed Melanie Lyons  |   |                        |   |                      |  |                    |
| Signature Many  |   | Lorar a                |   | Date                 | March 24, 2007   |                    |

CENTRAL FAX CENTER SP BIOPHARMA

🖾 002/007

## MAR 2 6 2007

Appl. No. 10/694,978 Amdt. dated March 26, 2007

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner: P.M. MERTZ

Jacqueline C. TIMANS

Art Unit: 1646

Application No.: 10/694,978

Conf. No.: 4528

Filed:

October 27, 2003

For:

**JL-1-LIKE CYTOKINE** 

ANTIBODIES (as amended)

I hereby certify that this correspondence is being transmitted by facsimile to the U.S. Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

Fax Number (571) 273-0876, on March 26, 2007

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL AMENDMENT

Honorable Sir:

In response to a telephone request by the Examiner on March 26, 2007, Applicants submit a revised claim set incorporating amendments to the claims filed on August 1, 2006 and on March 8, 2007. Applicants March 8, 2007 claim set inadvertently failed to incorporate the amendments filed August 1, 2006. Applicants respectfully request that the attached claim set be entered in place of the claim set filed March 8, 2007. Applicants apologize for any resulting confusion.

Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 6 of this paper.